Articles related to ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

Eighty-eight children ages 6 through 12 were randomized to daily pine bark extract, methylphenidate, or placebo for 10 weeks. Total ADHD-Rating Scales scores decreased 29% with pine bark extract, 45% with methylphenidate, and 5% with placebo. Hyperactivity/impulsivity decreased 34% with pine bark extract and 36% with methylphenidate and increased 1% with placebo. Inattention decreased 25% with pine bark extract, 52% with methylphenidate, 9% with placebo. Adverse events were reported 5 times more frequently with methylphenidate than with pine bark.

Teva Pharmaceuticals is the primary supplier of both branded and generic versions of the stimulant, which is approved to treat ADHD and narcolepsy. Teva has cited increased demand, workforce shortages, and manufacturing disruptions due to packaging constraints as reasons for the supply problems.

After reading this article, head over to this quiz to test your understanding of the findings of a triple-blind, crossover study that involved 173 ADHD-diagnosed children between the ages of 7 and 12. Children received daily education in science, social studies, and vocabulary for 25 minutes over the course of two successive sessions.

Watch Dr. Jain discuss his seven tips to help to gauge what is working, what is not working, and where there is room for improvement in treating and managing your adult patients with ADHD.